Author's response to reviews

Title: Targeting Molecular Resistance in Castration-Resistant Prostate Cancer

Authors:

Thenappan Chandrasekar (tchandrasekar@ucdavis.edu)
Joy C Yang (jcyang@ucdavis.edu)
Allen C Gao (acgao@ucdavis.edu)
Christopher P Evans (cpevans@ucdavis.edu)

Version: 4  Date: 9 August 2015

Author's response to reviews: see over
Dr. Alam:

Please find below a complete response to the second round of reviews submitted for our manuscript, as well as answers to additional questions posed in the response email.

First reviewer (specific concerns):

1) Use of the term “non-responder”, which is used throughout the study, but varies from study to study – Agree, amended to clarify. Radiographic progression at 3 months.

2) Include data from STAMPEDE trial which was just presented in ASCO – Agree, this has now been included.

Second review (specific concerns):

1) Please add some additional information on other AR targeting agents in clinical development (e.g. Bayer ODM201, ARN509, the ISIS/AZ AR antisense drug (Yamamoto et al CCR 2015), galaterone, VT-486, and the OGX427 (targeting the AT chaperone hsp27)). – Disagree. As mentioned in original response, we felt that for a review paper, we focused on approved therapies.

3) Please include results from the STAMPEDE trial from ASCO 2015 in support of CHAARTED data – Agree, this has now been included.

To address other issues in the formal response email (editorial requests):

1) Regarding the competing interests statement, please could you clarify the relevance of the Department of Defense for this manuscript?

   a. No specific relevance, part of our standard competing interest statement.
2) Thank you for providing confirmation about the sources of the figures. Please add statements to each figure legend to state the figure was made for this manuscript or reproduced with permission as appropriate. ***

a. Figure 2 previously published in Clinical Cancer Research; authors CPE, ACG and JCY are also authors on the original paper. Diagrams are owned by the author and permission has been granted for publication

b. Figure 1 has not been previously published in its current form

3) Please include an authors' information section at the end of the manuscript. More information can be found at http://www.biomedcentral.com/bmcmed/authors/instructions/review#formatting-information

Included in this online submission are:

1) Manuscript (revised)

2) Figure 1

3) Figure 2

If you have questions, please call me at (732) 742-1025 or email me at tchandrasekar@ucdavis.edu.

Sincerely,

Thenappan Chandrasekar, MD